AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2014
Sep 3, 2014
30583_dirs_2014-09-03_9e5bd111-310d-4932-9a22-eb381543f433.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2014-09-02
Reporting Person: SPIEGELMAN DANIEL K (EVP, Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-09-02 | Common Stock | M | 16000 | $39.06 | Acquired | 84676 | Direct |
| 2014-09-02 | Common Stock | S | 16000 | $69.8321 | Disposed | 68676 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-09-02 | Stock Option (right to buy) | $39.06 | M | 16000 | Disposed | 2022-05-28 | Common Stock (16000) | Direct |
Footnotes
F1: Transaction made pursuant to a Rule 1b5-1 plan executed on December 9, 2013
F2: The price in Column 4 is a weighted average price. The prices actually received ranged from $69.22 to $69.87. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Option grant vests 6/48ths on November 29, 2012 and 1/48th on the 29th day of every month thereafter.
F4: Reflects the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.